• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CAFFEINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CAFFEINE chembl:CHEMBL113 Approved

    Alternate Names:

    YEAST-VITE
    METHYLTHEOBROMINE
    CAFFEINE MELTING POINT STANDARD
    NODOZ
    ZANTHINE
    CAFFEINE
    PRO-PLUS
    THEINE
    CAFCIT
    ANHYDROUS CAFFEINE
    NSC-5036
    FEMA NO. 2224
    NODOZ CAPLETS AND CHEWABLE TABLETS
    COFFEINE
    1,3,7-TRIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
    3,7-DIHYDRO-1,3,7-TRIMETHYL-1H-PURINE-2,6-DIONE
    7-METHYL THEOPHYLLINE
    CAFÉINE
    COFFEINUM
    LANORINAL
    METHYLTHEOBROMIDE
    1-METHYLTHEOBROMINE
    1,3,7-TRIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE
    TEÍNA
    PROPOXYPHENE
    COFFEIN
    7-METHYLTHEOPHYLLINE
    1,3,7-TRIMETHYL-2,6-DIOXOPURINE
    ANHYDROUS CAFFEINE (JP15)
    THEIN
    HYCOMINE
    1,3,7-TRIMETHYLXANTHINE
    GUARANINE
    KOFFEIN
    CAFEÍNA
    MATEÍNA
    MONOHYDRATE CAFFEINE
    1-METHYL-THEOBROMINE
    METHYLXANTHINE THEOPHYLLINE
    1,3,7-TRIMETHYLPURINE-2,6-DIONE
    CAFFEINUM
    3,7-DIHYDRO-1,3,7-TRIMETHYL-1H-PURIN-2,6-DION
    1,3,7-TRIMETHYLPURINE-2,6-QUINONE
    chemidplus:58-08-2
    rxcui:1886
    drugbank:00201
    pubchem.compound:2519
    chembl:CHEMBL113

    Drug Info:

    FDA Approval not approved by the FDA
    Drug Class small molecule
    Drug Indications Central Nervous System Stimulants
    Year of Approval not approved by the fda
    Drug Class central nervous system stimulants
    (4 More Sources)

    Publications:

    Mustafa et al., 2006, Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?, Xenobiotica
    Rieg et al., 2007, Adenosine A1 receptors determine effects of caffeine on total fluid intake but not caffeine appetite., Eur. J. Pharmacol.
    Wang, 2007, Caffeine facilitation of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) through activation protein kinase C pathway: an interaction with presynaptic adenosine A1 receptors., Synapse
    Listos et al., Adenosine receptor antagonists intensify the benzodiazepine withdrawal signs in mice., Pharmacol Rep
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Gaytan et al., 2006, Effect of postnatal exposure to caffeine on the pattern of adenosine A1 receptor distribution in respiration-related nuclei of the rat brainstem., Auton Neurosci
    Zhao et al., 2007, Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist., J. Cardiovasc. Pharmacol.
    Riksen et al., 2007, The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo., Pharmacogenet. Genomics
    Cornelis et al., 2007, Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption., Am. J. Clin. Nutr.
    Domschke K et al., 2012, ADORA2A Gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex., Neuropsychopharmacology
    Rogers PJ et al., 2010, Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption., Neuropsychopharmacology
    Childs E et al., 2008, Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety., Neuropsychopharmacology
    Rétey JV et al., 2007, A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep., Clin Pharmacol Ther
    Alsene K et al., 2003, Association between A2a receptor gene polymorphisms and caffeine-induced anxiety., Neuropsychopharmacology
    Ribeiro et al., 2010, Caffeine and adenosine., J. Alzheimers Dis.
    Seo et al., 1999, Caffeine does not inhibit substance P-evoked intracellular Ca2+ mobilization in rat salivary acinar cells., Am. J. Physiol.
    Shibuya et al., 1999, Prostaglandin E2 induces Ca2+ release from ryanodine/caffeine-sensitive stores in bovine adrenal medullary cells via EP1-like receptors., J. Neurochem.
    Tohda et al., 1992, A possible involvement of DNA topoisomerase I in "caffeine effect" after ultraviolet irradiation., Tohoku J. Exp. Med.
    Sidorenko et al., 2008, Ionic strength and magnesium affect the specificity of Escherichia coli and human 8-oxoguanine-DNA glycosylases., FEBS J.
    Tong J et al., 1997, Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease., J Biol Chem
    Kondo T et al., 2018, Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia., J Anesth
    Sambuughin N et al., 2001, Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families., Neuromuscul Disord
    Daly, 2007, Caffeine analogs: biomedical impact., Cell. Mol. Life Sci.
    Mehiri et al., 2005, Time-based gene expression programme following diaphragm injury in a rat model., Eur. Respir. J.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Sara et al., 2004, The role of nitric oxide on contractile impairment during endotoxemia in rat diaphragm muscle., Eur. J. Pharmacol.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Kitagawa K et al., 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP., Biochem Biophys Res Commun
    Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
    Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
    Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
    Hirose T et al., 2010, Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer., Oncol Rep
    Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
    Tan L et al., 2010, The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients., Clin Neurol Neurosurg
    Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
    Murai K et al., 2009, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes., Xenobiotica
    Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
    di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
    Arab-Alameddine M et al., 2009, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals., Clin Pharmacol Ther
    Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
    Fujita K et al., 2008, CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1., Cancer Sci
    Kaida Y et al., 2008, The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer., Clin Pharmacol Ther
    Fukami T et al., 2007, A novel duplication type of CYP2A6 gene in African-American population., Drug Metab Dispos
    Peamkrasatam S et al., 2006, In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais., Drug Metab Pharmacokinet
    Audrain-McGovern J et al., 2007, The role of CYP2A6 in the emergence of nicotine dependence in adolescents., Pediatrics
    Benowitz NL et al., 2006, CYP2A6 genotype and the metabolism and disposition kinetics of nicotine., Clin Pharmacol Ther
    Nakajima M et al., 2006, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations., Clin Pharmacol Ther
    Nurfadhlina M et al., 2006, CYP2A6 polymorphisms in Malays, Chinese and Indians., Xenobiotica
    Minematsu N et al., 2006, Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms., Eur Respir J
    Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry
    Huang S et al., 2005, CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents., Pharmacogenet Genomics
    Kimura M et al., 2005, Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans., Drug Metab Dispos
    Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
    Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity., Drug Metab Dispos
    Gyamfi MA et al., 2005, High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana., Eur J Clin Pharmacol
    Fukami T et al., 2004, A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo., Clin Pharmacol Ther
    Schoedel KA et al., 2004, Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians., Pharmacogenetics
    Fujieda M et al., 2004, Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers., Carcinogenesis
    Yamanaka H et al., 2004, Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted., Eur J Pharm Sci
    Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
    Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
    Ando M et al., 2003, Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults., J Epidemiol
    Ariyoshi N et al., 2002, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers., Cancer Epidemiol Biomarkers Prev
    Daigo S et al., 2002, A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur., Pharmacogenetics
    Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles., Biochem Biophys Res Commun
    Zhang X et al., 2001, Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population., Nihon Arukoru Yakubutsu Igakkai Zasshi
    Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
    Tan W et al., 2001, Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population., Int J Cancer
    Ariyoshi N et al., 2001, A novel single nucleotide polymorphism altering stability and activity of CYP2a6., Biochem Biophys Res Commun
    Poland RE et al., 2000, Effect of cigarette smoking on coumarin metabolism in humans., Nicotine Tob Res
    Rao Y et al., 2000, Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking., Mol Pharmacol
    Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
    Vigh et al., 2003, Intracellular calcium release resulting from mGluR1 receptor activation modulates GABAA currents in wide-field retinal amacrine cells: a study with caffeine., Eur. J. Neurosci.
    Kunz et al., 1993, Mitochondrial oxidative phosphorylation in saponin-skinned human muscle fibers is stimulated by caffeine., FEBS Lett.
    Bassani et al., 1995, CaMKII is responsible for activity-dependent acceleration of relaxation in rat ventricular myocytes., Am. J. Physiol.
    Sampieri et al., 2005, The foot structure from the type 1 ryanodine receptor is required for functional coupling to store-operated channels., J. Biol. Chem.
    Oppelt et al., 2004, Role of intracellular calcium stores on the effect of metabotropic glutamate receptors on phosphorylation of glial fibrillary acidic protein in hippocampal slices from immature rats., Neurochem. Res.
    Sahir et al., 2004, Caffeine induces sonic hedgehog gene expression in cultured astrocytes and neurons., J. Mol. Neurosci.
    Hancock et al., 1988, Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E., J. Immunol.
    Rapuri et al., 2001, Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes., Am. J. Clin. Nutr.
  • CAFFEINE   TRPC1

    Interaction Score: 4.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15878845


    Sources:
    NCI

  • CAFFEINE   OGG1

    Interaction Score: 4.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18557781


    Sources:
    NCI

  • CAFFEINE   CYP2A6

    Interaction Score: 4.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10448083 21521021 21494765 20860463 20596643 20155256 20089352 19921195 19845430 19604090 19238117 19225447 18698229 18380793 18212800 17267622 17220563 17130279 17112802 16952495 16891249 16452582 16402128 16272956 15980104 15940289 15900015 15660270 15592323 15475735 15308589 15265511 14981342 12844137 12749606 12223434 12042667 11779172 11725533 11394901 11241319 11237731 11197315 10999944 10544257


    Sources:
    PharmGKB

  • CAFFEINE   SHH

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15456933


    Sources:
    NCI

  • CAFFEINE   LPAR2

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10199823


    Sources:
    NCI

  • CAFFEINE   GRM1

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12814357


    Sources:
    NCI

  • CAFFEINE   RYR1

    Interaction Score: 0.95

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    9334205 29344738 11525881 17514358


    Sources:
    PharmGKB

  • CAFFEINE   ADORA2A

    Interaction Score: 0.93

    Interaction Types & Directionality:
    multitarget
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Adenosine receptor antagonist

    PMIDs:
    11752352 17577101 17558310 17616786 22012471 20520601 18305461 17329997 12825092


    Sources:
    ChemblInteractions TEND PharmGKB TTD

  • CAFFEINE   ADORA1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    multitarget
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Adenosine receptor antagonist
    Trial Name -

    PMIDs:
    17162470 17126319 17372967 17085856 11752352 16702031


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • CAFFEINE   PTGER1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10537077


    Sources:
    NCI

  • CAFFEINE   MYO9B

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8495738


    Sources:
    NCI

  • CAFFEINE   PDE4B

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17514358 17016423 17139284


    Sources:
    TdgClinicalTrial TEND

  • CAFFEINE   ADORA2B

    Interaction Score: 0.31

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Adenosine receptor antagonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    20164566


    Sources:
    TdgClinicalTrial ChemblInteractions

  • CAFFEINE   CAMK2B

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7864197


    Sources:
    NCI

  • CAFFEINE   ADORA3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Adenosine receptor antagonist
    Direct Interaction yes

    PMIDs:
    20164566


    Sources:
    ChemblInteractions

  • CAFFEINE   FGF2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15738284


    Sources:
    NCI

  • CAFFEINE   GFAP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15260132


    Sources:
    NCI

  • CAFFEINE   IL2RA

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3129507


    Sources:
    NCI

  • CAFFEINE   NOS1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15556151


    Sources:
    NCI

  • CAFFEINE   TOP1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1339096


    Sources:
    NCI

  • CAFFEINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CAFFEINE   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11684540


    Sources:
    NCI

  • CAFFEINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CAFFEINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CAFFEINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CAFFEINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CAFFEINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: CAFFEINE

    • Version: 01-August-2011

    Alternate Names:
    CAFFEINE Primary Drug Name

    Drug Info:
    Drug Class central nervous system stimulants
    Year of Approval not approved by the fda

    Publications:

  • TdgClinicalTrial: CAFFEINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Central Nervous System Stimulants
    Drug Class small molecule
    FDA Approval not approved by the FDA

    Publications:

  • NCI: CAFFEINE

    • Version: 14-September-2017

    Alternate Names:
    C328 NCI drug code

    Drug Info:

    Publications:
    Kunz et al., 1993, Mitochondrial oxidative phosphorylation in saponin-skinned human muscle fibers is stimulated by caffeine., FEBS Lett.
    Sahir et al., 2004, Caffeine induces sonic hedgehog gene expression in cultured astrocytes and neurons., J. Mol. Neurosci.
    Hancock et al., 1988, Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E., J. Immunol.

  • DTC: CAFFEINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL113 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: caffeine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tong J et al., 1997, Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease., J Biol Chem
    Sambuughin N et al., 2001, Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families., Neuromuscul Disord
    Kondo T et al., 2018, Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia., J Anesth

  • TTD: Caffeine

    • Version: 2020.06.01

    Alternate Names:
    D0B3HD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL113

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL113

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21